Usefulness of the MESH score in a European hepatocellular carcinoma cohort

Table 1 Baseline characteristics in European hepatocellular carcinoma cohort (n = 581) n (%)

Patients characteristics	Cohort (n = 581)
Age, yr, mean ± SD	67.4 ± 11.7
Male	475 (82)
Etiology - HCV/HBV/Alcohol/MS/others	209 (36)/41 (7)/215 (37)/87 (15)/29 (5)
Cirrhosis	505 (87)
Child - Pugh stage1 A/B	323 (64)/182 (36)
Maximal tumor diameter, mean ± SD	60.9 ± 39.1
Tumor nodularities (1/2/≥ 3), n (%)	227 (39%)/76 (13%)/278 (48)
Infiltrative tumor	235 (40)
Extrahepatic metastasis	59 (10)
Vascular invasion	213 (37)
Performance status 0/1/2-4	276 (48)/136 (23)/169 (29)
Laboratory values (mean ± SD)
Alkaline phosphatase (IU/L) > 200	112 (19)
PT (%), mean ± SD	78.0 ± 15.8
Albumin (g/L), mean ± SD	34.7 ± 6.1
Aspartate transaminase (IU/L), mean ± SD	68.7 ± 60.7
Alpha-fetoprotein (ng/mL), mean ± SD	5680 ± 31332
Tumor stages
BCLC (A/B/C/D), n (%)	181 (31)/92 (16)/241 (41)/67 (12)
Treatment allocation
Resection or RFA, n (%)	131 (23)
TACE, n (%)	175 (30)
Sorafenib, n (%)	152 (26)
Supportive care, n (%)	123 (21)
Follow-up Time, mo, mean ± SD	18.3 ± 20.3
Deaths, n (%)	413 (71)
Overall Survival, mo, mean ± SD	26.0 ± 1.3

¹Cirrhotic patients. HCV: Hepatitis C virus; HBV: Hepatitis B virus; MS: Metabolic syndrom; PT: Prothrombin time; BCLC: Barcelona Clınic Liver Cancer; RFA: Radiofrequency ablation; TACE: Trans arterial chemoembolization.